Company intelligence / Profile preview

Biosenta

Toronto, Ontario, Canadabiosenta.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biosenta has launched its "true™" disinfectant product in North America with Health Canada recognition for COVID‑19 use. Its proprietary Tri-Filler® antimicrobial filler is being scaled from bench to commercial production and has demonstrated durable protection against a wide spectrum of microbes. Recent advances include successful bench-scale production exceeding expectations and licensing agreements for specialty concrete applications[2][5][8].

Therapeutic areas: Infectious Diseases
Modalities: NanoparticleSmall molecule
Industry: Non-Drug Biotech

Drug pipeline

2 assets

true

Commercial

Indications: Surface disinfection, COVID-19

1 more asset in the full pipeline.

Request access →

Partnerships

Lightweight Concrete Solutions – exclusive licensee of Tri-Filler® technology for specialty concrete products

Beyond the preview

Go deeper on Biosenta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosenta.

Explore the full profile